Recent Updates
Recently added Catalysts
RVTY Positive Sentiment

Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing

Monday, August 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Revvity, Inc. has launched the SuperFlex prenatal screening system, which is CE-IVDR certified. This compact immunoassay instrument aims to provide reliable and rapid preeclampsia testing solutions for laboratories and clinics. The system is designed for lower-volume workflows, addressing the growing need for effective prenatal screening as preeclampsia rates rise globally.

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of the SuperFlex prenatal screening system.
  • CE-IVDR certification enhances credibility.
  • Supports testing for preeclampsia, improving maternal health.

Full Press Release Details

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows. The system supports testing for preeclampsia, a condition that affects between 2% and 8% of pregnancies and is increasing globally due to rising maternal age and conditions such as diabetes an

Frequently Asked Questions

What is the SuperFlex prenatal screening system?

The SuperFlex is a compact, CE-IVDR certified immunoassay instrument for prenatal screening.

What condition does the SuperFlex test for?

It supports testing for preeclampsia, affecting 2% to 8% of pregnancies.

Why is preeclampsia testing important?

Preeclampsia is increasing globally, making effective screening essential for maternal health.

Who can benefit from the SuperFlex system?

Laboratories and clinics seeking reliable, rapid solutions for lower-volume workflows.

ShareAdd on Google
Tags: RVTY Viatris Investor Conferences Healthcare Revvity preeclampsia prenatal screening immunoassay maternal health
Last updated: Aug 10, 2026

Biotech snapshot

Cash runway
$860M liquidity · $0M/mo burn
Low dilution risk